Prioritizing a candidate's skills ('capacity') over their fit with the team ('chemistry') is a mistake. To scale culture successfully, focus on hiring people who will get along with their colleagues. The ability to collaborate and integrate is more critical for long-term success than a perfect resume.

Nike's first external CEO, Bill Perez, failed despite his credentials because he couldn't adapt to the company's unique, collaborative culture. He was accustomed to strict roles, which clashed with Nike's team-oriented atmosphere. This demonstrates that cultural fit can be more critical than a perfect resume for executive roles.

Vivtex's scientist-CEO successfully navigated the transition by hiring an experienced finance and operations lead early on. This freed him from learning non-R&D functions from scratch, allowing him to leverage his deep technical expertise for high-value activities like business development and scientific strategy.

Recursion's CEO Najat Khan argues that the key to success in tech-bio is not just hiring scientists and engineers, but cultivating a 'bilingual' culture. This requires scientists who understand AI's limitations and AI experts who appreciate the humility needed for science. This integrated talent and culture is a core competitive advantage that is difficult for larger, more siloed organizations to replicate.

Hiring for "cultural fit" can lead to homogenous teams and groupthink. Instead, leaders should seek a "cultural complement"—candidates who align with core values but bring different perspectives and experiences, creating a richer and more innovative team alchemy.

A biotech transitioning from a small, 'fit-for-purpose' R&D team to a large commercial organization gets a rare chance to create a new culture. Madrigal treated its rapid growth from ~100 to over 500 people as an opportunity to establish fresh core values for the newly-formed enterprise.

Beyond simple headcount growth, a biotech's culture must fundamentally shift as it matures. Moving into clinical trials requires a new focus on patient safety and regulation, while commercialization introduces intense pressure for compliance and revenue generation.

Developing a new medicine is 'the toughest team sport,' requiring hundreds of people across diverse disciplines over many years. In this context, culture isn't a perk; it's the fundamental 'glue' that enables these disparate teams to work in concert and succeed. Without it, even the best individual players will fail.

Brett Monia deliberately chose the University of Pennsylvania for his PhD to leverage its adjunct professor relationship with Smith-Kline. This decision provided direct access to industry leader Stanley Crook, who became his mentor and later recruited him as a founding scientist at Ionis.